Rachel Sava, PhD
Rachel Sava, PhD, is the program director for the McLean Institute for Technology in Psychiatry. She received her BA from Harvard University and PhD from the Weill Medical College of Cornell University, both in the field of neuroscience. Dr. Sava conducted her PhD studying the mechanisms underlying ketamine’s fast-acting antidepressant effects funded by a National Science Foundation Graduate Research Fellowship. Prior to working at McLean, Dr. Sava was a life science consultant at ClearView Healthcare Partners in Newton, Massachusetts, where she assisted pharmaceutical companies with market strategy, portfolio assessments, and competitive analysis.
Dr. Sava utilizes her experiences in academia, industry, and business to help propel the initiatives of the McLean Institute for Technology in Psychiatry and ultimately drive its mission to identify, innovate, and implement technologies that can significantly impact patient lives.